Wipfli Financial Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wipfli Financial Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$72K	Buy	+844	New	+$75.2K	0.01%	892

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wipfli Financial Advisors's BMRN Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2022: 844 shares worth $72K. The stake represents 0.01% of the portfolio and ranks #892 among its holdings.

551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Wipfli Financial Advisors held 844 shares of BioMarin Pharmaceuticals worth $72K as of Q3 2022.
BioMarin Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
BioMarin Pharmaceuticals made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #892 holding.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.